Ozen Metehan, Cokugras Haluk, Ozen Naile, Camcioglu Yildiz, Akcakaya Necla
Department of Pediatrics, Inonu University Medical Faculty, Malatya, Turkey.
Pediatr Int. 2004 Aug;46(4):429-35. doi: 10.1111/j.1442-200x.2004.01925.x.
This study aims to determine the relation between anabolic hormones, Insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3), growth parameters, and clinical status in prepubertal cystic fibrosis (CF) patients. This prospective study comprises age/sex-matched control subjects and was set in a tertiary care teaching hospital.
Serum concentrations of IGF-I and IGFBP-3 were measured in 37 CF and 23 healthy subjects, whose mean ages were 5.02 +/- 3.06 and 5.27 +/- 2.82, respectively. The results were analyzed in relation to body mass index standard deviation scores (BMISD), height standard deviation scores (HSD), growth velocity standard deviation scores (GVSD), and clinical status assessed by Shwachman scores and pulmonary function parameters.
Serum IGFBP-3 of CF patients showed significantly lower concentrations than healthy subjects (2457 vs. 3249 ng/mL) (P < 0.05), whereas IGF-I levels did not (123.35 vs. 149.8 ng/mL). There was significant positive correlation between IGF-I and IGFBP-3 with HSD (r = 0.62; r = 0.79) and BMISD (r = 0.39; r = 0.50). The pulmonary function tests in 14 CF subjects were not statistically worse than in nine healthy cases. The mean HSD (-0.67, SD 1.06) and BMISD (-0.28, SD 0.71) of CF patients were not significantly lower than those of healthy subjects (-0.02, SD 0.86 and 0.03, SD 0.49), respectively.
Decreased serum IGF-I and IGFBP-3 levels may reflect growth retardation in CF. IGFBP-3 seems like a more sensitive parameter than IGF-I for growth monitoring in this study. Growth parameters of Turkish prepubertal CF patients are not markedly below national standards. Different genetic backgrounds of relevant populations certainly play an important role for the variable clinical course.
本研究旨在确定青春期前囊性纤维化(CF)患者体内合成代谢激素、胰岛素样生长因子 -I(IGF-I)和IGF结合蛋白 -3(IGFBP-3)、生长参数及临床状况之间的关系。这项前瞻性研究纳入了年龄/性别匹配的对照受试者,研究地点为一家三级护理教学医院。
对37名CF患者和23名健康受试者的血清IGF-I和IGFBP-3浓度进行了测量,他们的平均年龄分别为5.02±3.06岁和5.27±2.82岁。研究结果依据体重指数标准差评分(BMISD)、身高标准差评分(HSD)、生长速度标准差评分(GVSD)以及通过Shwachman评分和肺功能参数评估的临床状况进行分析。
CF患者的血清IGFBP-3浓度显著低于健康受试者(2457对3249 ng/mL)(P < 0.05),而IGF-I水平则无显著差异(123.35对149.8 ng/mL)。IGF-I和IGFBP-3与HSD(r = 0.62;r = 0.79)以及BMISD(r = 0.39;r = 0.50)之间存在显著正相关。14名CF受试者的肺功能测试结果在统计学上并不比9名健康受试者差。CF患者的平均HSD(-0.67,标准差1.06)和BMISD(-0.28,标准差0.71)分别并不显著低于健康受试者(-0.02,标准差0.86和0.03,标准差0.49)。
血清IGF-I和IGFBP-3水平降低可能反映CF患者生长发育迟缓。在本研究中,IGFBP-3似乎是比IGF-I更敏感的生长监测参数。土耳其青春期前CF患者的生长参数并未明显低于国家标准。相关人群不同的遗传背景肯定对临床病程的差异起着重要作用。